{
  "ticker": "PYC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960800",
  "id": "02960800",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250623",
  "time": "0857",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06kzxxk6j5g63g.pdf",
  "summary": "### Key Material Information Summary:\n- **Regulatory Milestone**: FDA alignment on VP-001 registrational trial design for RP11 treatment, including:\n  - Acceptable sham control arm and inclusion/exclusion criteria.\n  - Choice of primary endpoint (LLVA or microperimetry).\n  - Minimum **24-month data requirement** for NDA (excluding accelerated approval potential).\n- **Clinical Progress**: VP-001 demonstrated **improvements in visual acuity (LLVA) and retinal sensitivity (microperimetry)** in Phase 1/2 RP11 trials.\n- **Next Steps**: Finalize registrational study design; FDA protocol endorsement (Type D meeting) targeted for **H2 2025**, followed by trial initiation.\n\n*No capital raising, financial data, or trading halt requested.*",
  "usage": {
    "prompt_tokens": 1533,
    "completion_tokens": 161,
    "total_tokens": 1694,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-22T23:12:48.745881"
}